Akari Therapeutics (AKTX) Other Operating Expenses (2015 - 2026)
Akari Therapeutics recorded quarterly Other Operating Expenses of $12.1 million in Q1 2026, up 421.58% quarter-over-quarter from -$3.8 million in Q4 2024.
Akari Therapeutics' Other Operating Expenses history runs 5 years deep, the most recent figure standing at $12.1 million for Q1 2026.
- In Q1 2026, Other Operating Expenses changed N/A year-over-year to $12.1 million; the TTM figure through Mar 2026 stood at $12.1 million (up 177.18% YoY), while the FY2025 annual figure was $5.2 million, up 126.17% from the prior year.
- Other Operating Expenses came in at $12.1 million for Q1 2026 at Akari Therapeutics, up from -$3.8 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $12.1 million in Q1 2026 to a low of -$7.6 million in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.13 Mn |
| Dec 31, 2024 | -3.77 Mn |
| Sep 30, 2024 | -4.39 Mn |
| Jun 30, 2024 | -7.56 Mn |
| Mar 31, 2024 | -7.61 Mn |
| Dec 31, 2021 | 11.94 Mn |
| Sep 30, 2021 | -430,157.00 |
| Dec 31, 2017 | 2.70 Mn |
| Sep 30, 2015 | 19.28 Mn |